Abstract:Objective To investigate the performance of DWI in the prediction of the response of gastrointestinal stromal tumor (GIST) to targeted therapy.Methods Twenty nine consecutive patients with unresectable GIST confirmed by pathology were enrolled in this prospective study.All patients were treated by imatinib mesylate single drug,and had at least one targeted lesion with longest diameter＞ 1 cm.MRI examinations were performed prior to and 2 weeks and 3 months afollowing treatment.The ADC of the whole lesion (ADCentire) and obviously high signal area on DWI (ADCmin) and the longest diameter (LD) on T2WIs were measured.The early percentage changes of the quantitative indicators (％ Δ LD,％ Δ ADCmin and ％ ΔADCentire) were calculated.All patients were divided into good response (GoodR) and poor response (PoorR) groups according to the combined response assessment criteria.The pre-therapy values and early percentage changes (％Δ) of the above quantitative parameters were compared using t test or Mann-Whitney U test.Receiver operating characteristic (ROC) curves were employed to compare the performance of the above quantitative parameters in the discrimination of response groups.Results A total of 82 lesions in 29 patients were included in the study.There were 57 lesions of GoodR and 25 lesions of PoorR.The pre-therapy baseline ADCmin and ADC in GoodR group were both lower than PoorR group [ADCmin:(0.90± 0.27) × 10-3 mm2/s vs.(1.15± 0.29) × 10-3 mm2/s,t=3.673,P＜0.01 ;ADCentire:(1.06 ± 0.26) × 10-3mm2/s vs.(1.31 ± 0.32) × 103mm2/s,t=3.698,P＜0.01].No statistical difference in baseline LD was displayed (P＞0.05).The ％ ΔADC ％ΔADC and ％ΔLD all had statistical difference between GoodR and PoorR groups(％ΔADCmin:48％ vs.3％,Z=-5.310,P＜0.01;％ΔADCentire:45％ vs.2％,Z=-5.768,P＜0.01;％ΔLD:-6％ vs.-1％,Z=-2.752,P＜0.01).Through ROC curves,the AUCs for pre-therapy ADCmin,ADCentire and LD were 0.735,0.721 and 0.503,respectively; and AUCs for ％ΔADCmin,％ΔADCentire and ％ΔLD after two weeks of therapy were 0.859,0.877 and 0.694,respectively,in the differentiation of responses.Using ％ ΔADCmin ≥ 13％ to predict GoodR,the sensitivity was 0.842 and specificity 0.760; Using ％ΔADCentire ≥ 22％ to predict GoodR,the sensitivity was 0.862 and specificity 0.800.Conclusions The percentage changes of the ADC after two weeks of therapy outperform the longest diameter and pre-therapy baseline ADC in the response predictionof GIST to targeted therapy.It is more effective of ADCentire than ADCmin values in the respo nse prediction.

MRI T1 Contrast-Enhanced Signal Intensity is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis

The Value of MRI in Evaluating the Therapeutic Effect of Desmoid-Type Fibromatosis

Value of Imaging Findings in Predicting Post-Operative Recurrence of Desmoid-Type Fibromatosis

Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs)

Desmoid-type Fibromatosis: Tumour Response Assessment Using Magnetic Resonance Imaging Signal and Size Criteria.

Features of Ultrasound and Contrast Enhanced Ultrasound in Superficial Desmoid-Type Fibromatosis: A Series of 19 Cases

The Therapeutic Response Of Gastrointestinal Stromal Tumors To Imatinib Treatment Assessed By Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging With Histopathological Correlation (Vol 11, E0167720, 2016)

The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation

Monitoring imatinib decreasing pericyte coverage and HIF-1α level in a colorectal cancer model by an ultrahigh-field multiparametric MRI approach

Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients.

Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma.

Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution.

Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma

Imaging features of extra-abdominal desmoid-type fibromatosis

Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions

Tumor Infiltration of Bone Marrow in Patients with Hemato-Logical Malignancies: Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Target Therapy of Unresectable or Metastatic Dermatofibrosarcoma Protuberans with Imatinib Mesylate an Analysis on 22 Chinese Patients

Signs of Tumor Infiltration of Bone Marrow in Patients with Hematological Malignancies on Dynamic Contrast-Enhanced MR Imaging: Preliminary Results

Imaging Features and Pathologic Correlations of Desmoid-Type Fibromatoses

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence from a Retrospective Study

MR diffusion weighted imaging in the prediction of the response of unresectable gastrointestinal stromal tumor to targeted therapy